GEETA, GEETA

GEETA, GEETA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 15 di 15 (tempo di esecuzione: 0.019 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 02 - Intervento a convegno 2017 Farina, FCeccon, MMori, SVerga, LBorin, LMMologni, LFontana, DGEETA, GEETAPiazza, RGambacorti-Passerini, C
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 01 - Articolo su rivista 2018 Mologni, LSharma, GGViltadi, MMassimino, LCitterio, SPurgante, SRaman, HPirola, APiazza, RGambacorti-Passerini, C +
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 02 - Intervento a convegno 2018 GEETA, GEETARedaelli, SCeccon, MGambacorti-Passerini, CMologni, L +
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 01 - Articolo su rivista 2018 Redaelli, SaraCeccon, MonicaSharma, Geeta GMastini, CristinaMauri, MarioMassimino, LucaCordani, NicolettaFarina, FrancescaPiazza, RoccoGambacorti-Passerini, CarloMologni, Luca +
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 01 - Articolo su rivista 2018 Sharma, GGMologni, LGambacorti-Passerini, C +
We shall overcome (drug resistance) some day 01 - Articolo su rivista 2019 Geeta, GeetaMologni, Luca
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 01 - Articolo su rivista 2019 Sharma, Geeta GeetaMastini, CristinaMologni, LucaGambacorti-Passerini, Carlo +
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 01 - Articolo su rivista 2019 Sharma G. G.Cortinovis D.Villa M.Cordani N.Bidoli P.Pagni F.Piazza R.Gambacorti-Passerini C.Mologni L. +
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 02 - Intervento a convegno 2019 Bossi ESteidl CFontana DSharma GGMologni LPiazza RGGambacorti Passerini C +
In vitro and in vivo characterization of resistance to lorlatinib treatment in ALK mutated cancers 07 - Tesi di dottorato Bicocca post 2009 2019 GEETA, GEETA
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma 01 - Articolo su rivista 2020 Sharma G. G.Gambacorti Passerini C.Mologni L. +
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 01 - Articolo su rivista 2020 Bossi E.Aroldi A.Steidl C.Verga L.Fontana D.Sharma G. G.Mologni L.Piazza R.Gambacorti Passerini C. +
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 01 - Articolo su rivista 2021 Sharma G. G.Mologni L.Gambacorti Passerini C. +
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 01 - Articolo su rivista 2021 Villa M.Sharma G. G.Manfroni C.Cortinovis D.Mologni L.
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 01 - Articolo su rivista 2021 Sharma, GGVilla, MMauri, MCrespiatico, IFontana, DMastini, CMagistroni, VCeccon, MRedaelli, SMassimino, LPiazza, RGambacorti Passerini, CMologni, L +